Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 5/20 | 0.52 |
| ▸ | AKT1 | P31749 | 4/20 | 0.52 |
| ▸ | AKT2 | P31751 | 4/20 | 0.52 |
| ▸ | AKT3 | Q9Y243 | 4/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.52 |
| ▸ | PRKCA | P17252 | 3/20 | 0.52 |
| ▸ | PRKCB | P05771 | 2/20 | 0.52 |
| ▸ | PRKACA | P17612 | 2/20 | 0.52 |
| ▸ | PRKACB | P22694 | 2/20 | 0.52 |
| ▸ | PKN1 | Q16512 | 2/20 | 0.52 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.52 |
| ▸ | CIT | O14578 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 12/20 | 0.46 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3335485 | 0.88 | ROCK1 (0.49) | ROCK1AKT1AKT2AKT3ROCK2 | |
| SCHEMBL14114804 | 0.86 | AKT1 (0.54) | ROCK1AKT1AKT2AKT3ROCK2 | |
| SCHEMBL1529641 | 0.86 | AKT1 (0.54) | ROCK1AKT1AKT2AKT3ROCK2 | |
| SCHEMBL3329879 | 0.85 | MAPK1 (0.43) | ROCK1AKT1AKT2AKT3ROCK2 | |
| SCHEMBL3335417 | 0.82 | ROCK1 (0.56) | ROCK1AKT1AKT2AKT3ROCK2 | |
| SCHEMBL1529608 | 0.82 | AKT1 (0.64) | ROCK1AKT1AKT2AKT3ROCK2 | |
| SCHEMBL14114815 | 0.82 | AKT1 (0.64) | ROCK1AKT1AKT2AKT3ROCK2 | |
| SCHEMBL21977550 | 0.81 | ROCK1 (0.52) | ROCK1AKT1AKT2AKT3ROCK2 | |
| SCHEMBL3333049 | 0.81 | ROCK1 (0.52) | ROCK1AKT1AKT2AKT3ROCK2 | |
| SCHEMBL3328881 | 0.79 | AKT1 (0.41) | ROCK1AKT1AKT2AKT3ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137338-A1 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION | 2010-06-03 | — | — | US | claimed |
| US-20210379021-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | RACE ONCOLOGY LTD (AU) | 2021-12-09 | — | — | US | disclosed |
| US-11147800-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2021-10-19 | — | — | US | disclosed |
| US-11135201-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2021-10-05 | — | — | US | disclosed |
| CN-113365610-A | Methods of making and delivering bisantrene formulations | 现代化制药公司 | 2021-09-07 | — | — | CN | disclosed |
| EP-3860575-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | Race Oncology Ltd. (AU) | 2021-08-11 | — | — | EP | disclosed |
| US-20200163940-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | RACE ONCOLOGY LTD. (AU) | 2020-05-28 | — | — | US | disclosed |
| US-20200163939-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | SG CREDIT PARTNERS, INC. | 2020-05-28 | — | — | US | disclosed |
| WO-2020072948-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | RACE ONCOLOGY LTD. (AU) | 2020-04-09 | — | — | WO | disclosed |
| US-10548876-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2020-02-04 | — | — | US | disclosed |
| EP-3024457-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE | Update Pharma Inc. (US) | 2016-06-01 | — | — | EP | disclosed |
| WO-2015013581-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE | UPDATE PHARMA INC. (US) | 2015-01-29 | — | — | WO | disclosed |
| WO-2015013579-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE | UPDATE PHARMA INC. (US) | 2015-01-29 | — | — | WO | disclosed |
| US-8338434-B2 | Inhibitors of Akt activity | GLAXOSMITHKLINE LLC (US) | 2012-12-25 | — | — | US | disclosed |
| US-8338434-B2 | Inhibitors of Akt activity | GLAXOSMITHKLINE LLC (US) | 2012-12-25 | — | — | US | disclosed |
| US-8338434-B2 | Inhibitors of Akt activity | GLAXOSMITHKLINE LLC (US) | 2012-12-25 | — | — | US | disclosed |
| US-20100137338-A1 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION | 2010-06-03 | — | — | US | disclosed |
| US-20100137338-A1 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION | 2010-06-03 | — | — | US | disclosed |
| US-20100137338-A1 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION | 2010-06-03 | — | — | US | disclosed |
| WO-2008121786-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200163939-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, CYP11B1, MCL1 | ROCK1 1875/4885AKT1 1216/4885AKT2 1329/4885 |
| US-20100137338-A1 | INHIBITORS OF Akt ACTIVITY | PI4KB, AKT3, AKT2 | ROCK1 414/4885AKT1 4/4885AKT2 3/4885 |
| US-11135201-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, HCCS, MCL1 | ROCK1 1421/4885AKT1 1236/4885AKT2 1565/4885 |
| US-11147800-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, CYP11B1, MCL1 | ROCK1 1875/4885AKT1 1216/4885AKT2 1329/4885 |
| US-20210379021-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | CYP3A43, CYP1A1, UGT1A3 | ROCK1 2034/4885AKT1 3945/4885AKT2 4183/4885 |
| US-20200163940-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, HCCS, MCL1 | ROCK1 1421/4885AKT1 1236/4885AKT2 1565/4885 |
| US-10548876-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, CYP11B1, CYP11B2 | ROCK1 1476/4885AKT1 1680/4885AKT2 1869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.